And these data are really quite interesting and impressive that if you don't progress and that your time on [enfortumab ...
Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback